Investigators searching for 5-Amino-1MQ on ClinicalTrials.gov often seek human clinical dataset references for this small-molecule enzyme inhibitor. Currently, 5-Amino-1MQ is an investigational research compound evaluated primarily in cell culture assays and animal models, with no formal phase II or phase III human clinical trials registered under its chemical identifier on the public registry. This resource provides a detailed analysis of the available preclinical literature, its biochemical mechanism as a membrane-permeable NNMT inhibitor, and strict quality verification protocols for laboratory applications.
Investigators searching for 5-Amino-1MQ on ClinicalTrials.gov often seek human clinical dataset references for this small-molecule enzyme inhibitor. Currently, 5-Amino-1MQ is an investigational research compound evaluated primarily in cell culture assays and animal models, with no formal phase II or phase III human clinical trials registered under its chemical identifier on the public registry. This resource provides a detailed analysis of the available preclinical literature, its biochemical mechanism as a membrane-permeable NNMT inhibitor, and strict quality verification protocols for laboratory applications.
A search for 5-Amino-1MQ on ClinicalTrials.gov yields zero active, completed, or recruitment-phase human clinical trials registered under its specific chemical name or small-molecule identifier. 5-Amino-1MQ is currently categorized strictly as an investigational research compound for laboratory and preclinical evaluation, rather than an FDA-approved therapeutic undergoing formal human clinical development.
The absence of ClinicalTrials.gov listings reflects the molecule's current developmental phase. While many research compounds generate substantial clinical interest due to compelling target biology, regulatory registry listings require formal Investigational New Drug (IND) applications or international equivalent approvals for human administration. Researchers evaluating the published literature on 5-Amino-1MQ must rely on peer-reviewed preclinical studies, in vitro enzyme kinetics, and in vivo rodent models rather than human clinical trial registries.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing N1-methylnicotinamide (MNAM) and S-adenosylhomocysteine (SAH). In adipose, hepatic, and cancer tissue lines, elevated NNMT activity acts as a metabolic sink, depleting both methyl donors and nicotinamide availability necessary for the NAD+ salvage pathway.
5-Amino-1MQ (5-amino-1-methylquinolinium) was synthesized as a cell-permeable, selective inhibitor of NNMT. In vitro enzymatic assays demonstrate that 5-Amino-1MQ directly binds the catalytic site of NNMT, preventing the methylation of nicotinamide. Preclinical data indicate that by blocking this clearance pathway, 5-Amino-1MQ preserves intracellular pools of NAM and SAM, altering cellular methyl balance and shunting nicotinamide back into the synthesis of nicotinamide adenine dinucleotide (NAD+). Researchers interested in enzyme kinetics and metabolic fluxes can review related pathway molecules in our research library.
The primary downstream biochemical consequence of NNMT inhibition observed in vitro is the elevation of cellular NAD+ concentrations. In rodent adipocyte models, application of 5-Amino-1MQ resulted in measurable increases in intracellular NAD+ levels compared to untreated controls. Because NAD+ serves as a critical coenzyme for sirtuins (specifically SIRT1 and SIRT3) and poly(ADP-ribose) polymerases (PARPs), preserving NAD+ availability alters mitochondrial bioenergetics.
Preclinical studies suggest that elevated NAD+ driven by 5-Amino-1MQ administration stimulates mitochondrial biogenesis and oxygen consumption rates (OCR) in cultured cellular assays. In vitro fluorometric assays demonstrate increased expression of key mitochondrial proteins, including peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and citrate synthase. These molecular shifts point toward enhanced oxidative phosphorylation efficiency, making 5-Amino-1MQ a primary subject of investigation in cellular bioenergetics and metabolic research.
Elevated NNMT activity has been strongly correlated with obesity, insulin resistance, and impaired basal metabolic rates in preclinical rodent models. When researchers administered 5-Amino-1MQ to mice fed a high-fat diet, preclinical data indicated a reduction in diet-induced weight gain and adipocyte hypertrophy without alterations in caloric intake.
Microscopic examination of tissue samples in these animal studies demonstrated enhanced lipolysis, reduced intracellular lipid accumulation, and improved systemic glucose tolerance parameters. By targeting the NNMT-dependent metabolic sink, 5-Amino-1MQ appears to increase basal energy expenditure at the cellular level. Researchers exploring metabolic regulation can contrast these findings with studies examining NNMT inhibitors and NAD+ pathways across various mammalian tissue explants.
Within preclinical metabolic research, 5-Amino-1MQ occupies a unique niche compared to other mitochondrial and metabolic modulators. While 5-Amino-1MQ directly targets enzyme-mediated nicotinamide clearance to preserve NAD+, peptide compounds like MOTS-c function as mitochondrial-derived signaling peptides that directly regulate nuclear gene expression and folate-methionine metabolism. Conversely, growth hormone secretagogues such as Tesamorelin alter lipid clearance through the central GH/IGF-1 axis rather than intracellular methyltransferase inhibition.
Understanding these distinct pathways is critical when designing multi-target in vitro assays or preclinical animal trials. Whereas peptide hormone analogues modulate cell surface receptors to trigger secondary messenger cascades, small-molecule inhibitors like 5-Amino-1MQ penetrate the plasma membrane to directly bind intracellular catalytic enzymes.
5-Amino-1MQ is typically synthesized as a iodide or chloride salt in microcrystalline powder form. For in vitro cell culture protocols, stock solutions should be prepared using high-purity dimethyl sulfoxide (DMSO) or sterile laboratory-grade solvents, as aqueous solubility varies depending on the salt form and pH of the buffer system.
Lyophilized and crystalline stocks should be stored at -20°C in a desiccated environment protected from direct light exposure. Once reconstituted in DMSO, aliquots should be stored at -80°C to prevent freeze-thaw degradation cycles. Researchers performing spectrophotometric or enzymatic assays should verify solvent compatibility and final DMSO concentrations (typically <0.1% v/v in cell culture media) to eliminate vehicle toxicity artifacts in experimental readings.
Given the reliance on empirical laboratory data, research integrity requires verified compound purity and identity. Substandard chemical reagents containing residual heavy metals, unreacted intermediates, or endotoxins can alter cellular viability and invalidate enzymatic binding metrics.
PX1 Research enforces rigorous multi-stage analytical protocols for all catalog compounds. Every batch of 5-Amino-1MQ undergoes reverse-phase high-performance liquid chromatography (RP-HPLC) to confirm chromatographic purity exceeding 98%, alongside electrospray ionization mass spectrometry (ESI-MS) to verify molecular weight and structure. Laboratories acquiring compounds through our wholesale lab portal receive lot-specific Certificates of Analysis (COAs) generated by independent ISO 17025 accredited testing facilities, ensuring verified lot traceability and endotoxin testing compliance.
Although current preclinical literature provides robust foundational evidence regarding NNMT inhibition, substantial translational research gaps remain. The lack of clinical trials on registry databases highlights the need for further pharmacokinetic, pharmacodynamic, and long-term toxicity evaluations in non-rodent mammalian models before potential human translational studies could be registered.
Current research initiatives focus on refining target specificity, characterizing potential off-target methyltransferase inhibition, and mapping the downstream epigenetic impacts of altered SAM/SAH ratios. As laboratory investigation advances, published literature will continue to expand the scope of 5-Amino-1MQ in cellular aging, metabolic homeostasis, and skeletal muscle physiology.
Why is 5-Amino-1MQ not listed with active trials on ClinicalTrials.gov?
ClinicalTrials.gov registers human clinical trials regulated by governmental bodies like the US FDA. 5-Amino-1MQ is currently an investigational small-molecule compound restricted to preclinical and laboratory research use; it has not yet progressed to formal FDA-registered phase II/III human trials.
What is the primary enzymatic target of 5-Amino-1MQ?
5-Amino-1MQ functions as a membrane-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme responsible for methylating nicotinamide and depleting cellular NAD+ salvage pathways.
How does 5-Amino-1MQ elevate cellular NAD+ in research models?
By inhibiting NNMT, 5-Amino-1MQ prevents the conversion of nicotinamide (NAM) into 1-methylnicotinamide (MNAM). This preserves the pool of available NAM, allowing it to be recycled back into NAD+ via the salvage pathway.
What analytical methods verify the purity of PX1 Research 5-Amino-1MQ?
PX1 Research utilizes reverse-phase high-performance liquid chromatography (RP-HPLC) to confirm purity (>98%) and electrospray ionization mass spectrometry (ESI-MS) for exact mass verification. All batches undergo third-party testing at ISO 17025 accredited laboratories.
What solvent is recommended for reconstituting 5-Amino-1MQ for cell assays?
5-Amino-1MQ powder is most readily dissolved in laboratory-grade DMSO to create concentrated stock solutions. Working dilutions are subsequently prepared in cell culture media, ensuring final DMSO concentrations remain below cytotoxic thresholds.
Are endotoxin levels tested for PX1 Research compounds?
Yes. Every lot is subjected to Chromogenic LAL or recombinant Factor C assays to verify that endotoxin levels meet strict research specifications prior to laboratory distribution.
How does 5-Amino-1MQ compare to MOTS-c in metabolic research?
5-Amino-1MQ is a synthetic small-molecule NNMT inhibitor that preserves NAD+ and alters intracellular methylation. MOTS-c is a mitochondria-derived peptide that translocates to the cell nucleus to modulate metabolic stress response genes.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in domestic, GMP-compliant facilities in the USA and shipped directly from our primary distribution hubs located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.